Thomas Jefferson University (TJU) has made cancer research one of its primary institutional priorities. The Jefferson Cancer Center (JCC) was established with the following mission: To increase the survival and quality of life of cancer patients by translating basic science discoveries into new strategies to diagnose, prevent and cure human cancer. To that end Dr. Carlo M. Croce, an expert in basic cancer research, was recruited as Director of the Jefferson Cancer Center in 1991 to establish first a strong research base for the Cancer Center. Subsequently major efforts were made to develop further the opportunities to forge a link between clinical programs and the basic science investigators. Dr. Robert L. Comis, who has substantial experience developing cancer related medical science programs, was recruited in 1993 to lead all of the clinically related patient care, teaching and research programs at Thomas Jefferson University. Working together, they have organized the scientific programs and administrative structure presented in this CCSG application. As Director, Dr. Croce has full authority for cancer related recruitment, space and resource allocation for the Jefferson Cancer Center, working in concert with the Dean, Dr. Comis and, where appropriate, other Department Chairpersons. The scientific program is divided into two interactive units: the Basic Science Division, under Dr. Croce's direction and the Medical Science Division, under Dr. Comis. The former includes five Established Programs: Cell Biology, Signal Transduction, Molecular Biology and Genetics, Structural Biology and Immunology; the latter includes: Developmental Therapeutics, Melanoma and Leukemia/Lymphoma, as well as two developing Programs: Prostate Cancer and Gastrointestinal Cancer. Thirteen shared resources support the scientific activity and two new clinically oriented resources support the resurgence in clinical trials research and human tissue procurement. All programs are focused on cancer, and interactions to maximize the synergy between scientific discovery and human oncology are abetted by this common interest and commitment of the leadership of the Jefferson Cancer Center and Thomas Jefferson University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA056036-03S1
Application #
2834594
Study Section
Cancer Center Support Review Committee (CCS)
Program Officer
Shafik, Hasnaa
Project Start
1995-06-22
Project End
2001-05-31
Budget Start
1997-07-15
Budget End
2001-05-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications